WRF
INSY

Waddell & Reed Financial’s Insys Therapeutics, Inc. INSY Stock Holding History

Waddell & Reed Financial’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-103,700
Closed -$1.66M – 638
2016
Q1 		$1.66M Sell
103,700
-38,700
-27% -$735K ﹤0.01% 580
2015
Q4 		$4.08M Sell
142,400
-70,900
-33% -$1.96M 0.01% 512
2015
Q3 		$6.07M Sell
213,300
-93,832
-31% -$3.45M 0.01% 475
2015
Q2 		$11M Buy
307,132
+21,932
+8% +$683K 0.02% 418
2015
Q1 		$8.29M Buy
285,200
+32,000
+13% +$846K 0.01% 450
2014
Q4 		$5.34M Buy
+253,200
New +$5.01M 0.01% 480

Other funds holding INSY

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Waddell & Reed Financial's INSY Position: Q2 2016 in Review

Waddell & Reed Financial sold out of Insys Therapeutics, Inc. (INSY) in Q2 2016, closing a stake of 103,700 shares — an estimated $1.66M sold.

Waddell & Reed Financial first reported a position in INSY in Q4 2014 and held it in 6 quarters. The position peaked at $11M in Q2 2015. 124 funds tracked by Wall St. Rank hold INSY as of Q2 2016.

  • Waddell & Reed Financial reported no remaining Insys Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Waddell & Reed Financial sold 103,700 Insys Therapeutics, Inc. shares in Q2 2016, an estimated $1.66M.
  • Waddell & Reed Financial first reported a position in Insys Therapeutics, Inc. in Q4 2014 and held it in 6 quarters.
  • Waddell & Reed Financial's Insys Therapeutics, Inc. position peaked at $11M in Q2 2015.
  • 124 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2016.

Based on Waddell & Reed Financial's 13F filing for Q2 2016, filed 12 Aug 2016.